Advanced Science | Mechanistic Study of PD-L1 and Immune Microenvironment Reprogramming in Inflammatory Breast Cancer

This study systematically reveals the PD-L1-mediated immune escape mechanism in inflammatory breast cancer, providing a critical theoretical foundation for designing combination immunotherapies based on the regulation of TAMs and T cell functions, thereby advancing our understanding of the transformation pathways in immune-cold tumor microenvironments.

 

Literature Overview

This article, 'Reprogramming the Immune Landscape of Inflammatory Breast Cancer,' published in the journal Advanced Science, systematically investigates the unique immunosuppressive tumor microenvironment (TME) of inflammatory breast cancer (IBC) and its impact on immunotherapy response. By integrating multi-omics and spatial transcriptomic data, the study deeply analyzes the interaction networks among stromal and immune cells—such as TAMs, T cells, DCs, and MSCs—in shaping immune-privileged niches. It proposes strategies to reprogram the TME by targeting key nodes such as PD-L1 and AXL to enhance antitumor immune responses. The research further evaluates the clinical trial progress and challenges of current immune checkpoint inhibitors (ICIs) in IBC, emphasizing the importance of integrating multidimensional biomarkers for patient stratification.

Background Knowledge

1. Inflammatory breast cancer (IBC) is a highly aggressive subtype of breast cancer, accounting for 1%–5% of all breast cancer cases but contributing to 7%–10% of breast cancer-related deaths, with a 5-year survival rate of only about 40%. It is characterized by rapid progression, early metastasis, and treatment resistance. Clinical diagnosis is often delayed due to atypical symptoms (e.g., skin redness, peau d'orange), and the lack of specific targeted therapies creates an urgent need for novel treatment strategies. 2. Although PD-L1 is widely used as a predictive biomarker for the efficacy of immune checkpoint inhibitors in various cancers, its relationship with prognosis in IBC remains controversial: some studies show that high PD-L1 expression correlates with better pathological complete response (pCR), while others report an association with poorer overall survival (OS), highlighting the functional complexity and detection heterogeneity of PD-L1 in IBC. Furthermore, a TME dominated by immunosuppressive components such as TAMs and TGF-β leads to T cell exhaustion and spatial exclusion, forming an 'immune-cold' phenotype that significantly diminishes the efficacy of ICIs. 3. This study focuses on systematically dissecting the immune cell interaction network in IBC, particularly the paracrine/autocrine signaling circuits between TAMs and tumor cells (e.g., IL-8/JAK2/STAT3, CSF1/CSF1R, AXL signaling), revealing their central roles in driving immune evasion and therapy resistance. It further proposes intervention strategies targeting these pathways to achieve a 'cold-to-hot' TME transformation, bridging the gap between the immunobiological mechanisms of IBC and clinical translation.

 

 

Research Methods and Experiments

The authors employed a comprehensive approach combining immunophenotyping, single-cell RNA sequencing (scRNA-seq), spatial transcriptomics, and multi-omics integration to systematically compare the composition and functional states of immune and stromal cells in tumor samples from IBC and non-IBC patients. Flow cytometry and immunohistochemistry were used to validate the spatial distribution and density of CD163+ TAMs, FOXP3+ Tregs, and CD8+ T cells. Using preclinical IBC mouse models (e.g., the SUM149 xenograft model), the impact of targeting CSF1R or AXL on TAM recruitment and polarization was assessed. Patient samples from clinical trials such as NCT03742986 were analyzed to correlate PD-L1 expression, TIL density, T cell clonality, and treatment responses (e.g., pCR, PFS).

Key Conclusions and Perspectives

• TAMs are highly enriched in the IBC tumor microenvironment and predominantly exhibit an M2-like phenotype, expressing markers such as CD163 and CD206. Their density correlates with activation of inflammatory and proliferative pathways and is positively associated with pCR—suggesting TAMs may have dual functions, necessitating further subpopulation stratification to guide targeted strategies
• The expression status of PD-L1 on TAMs determines their functional phenotype: PD-L1+ TAMs exhibit immunostimulatory characteristics and are located near T cells, whereas PD-L1− TAMs reside around tumor nests and display immunosuppressive properties—indicating that PD-L1 not only functions on tumor cells but also serves as a key regulatory molecule in TAM function
• IBC cells recruit monocytes and induce their M2 polarization by secreting factors such as CCL2, CSF1, and VEGFA, which in turn promote cancer cell stemness and invasiveness via the IL-8/JAK2/STAT3 pathway—revealing a positive feedback loop between TAMs and tumor cells as a potential intervention node
• The AXL signaling pathway regulates TAM recruitment and polarization; inhibiting AXL reduces CD206+ TAM infiltration and downregulates immunosuppressive factors such as CCL20 and CCL26—supporting AXL as a therapeutic target for TME reprogramming
• High T cell clonality and TIL density are associated with pCR and longer PFS, while increased CTC counts accompany CD8+ T cell functional exhaustion—emphasizing that the state of adaptive immune activation is a crucial predictor of ICI efficacy
• Despite high PD-L1 expression and the presence of T cell exhaustion markers (e.g., PD-1, TIM-3, LAG-3) in IBC, monotherapy with ICIs shows limited efficacy—indicating that simply blocking PD-1/PD-L1 is insufficient to reverse deep immunosuppression, necessitating combination strategies

Research Significance and Prospects

This study provides a mechanistic framework for developing precision immunotherapies for IBC. Targeting TAMs (e.g., anti-CSF1R, anti-AXL) or their secreted factors (e.g., IL-8) could serve as foundational combination strategies with ICIs to alleviate immunosuppression and promote T cell infiltration. Additionally, patient stratification using dynamic biomarkers such as T cell clonality and spatial immune features will enhance the precision of ICI treatment. Future efforts should focus on mechanism-driven adaptive clinical trial designs and integrating multi-omics data to optimize combination strategies.

 

 

Conclusion

Inflammatory breast cancer has been considered an 'immune desert' due to its highly immunosuppressive tumor microenvironment. This study systematically maps its complex immune landscape, revealing the interactive network among TAMs, T cell exhaustion, and dynamic PD-L1 regulation. It not only explains the fundamental reasons for the limited efficacy of current immune checkpoint inhibitors in IBC but also proposes translational strategies to reprogram the TME by targeting pathways such as CSF1, AXL, or IL-8. From bench to bedside, these findings lay the theoretical foundation for designing 'cold-to-hot' tumor conversion strategies, advancing a new paradigm of combination immunotherapy centered on PD-L1 but extending beyond single-target approaches. Particularly for subpopulations with high TILs or specific immune gene signatures, combination therapies hold promise for overcoming resistance. Future efforts should establish standardized immune profiling systems and leverage genetically engineered animal models (e.g., humanized mice) to validate the effects of target interventions, accelerating the translation from mechanistic discovery to clinical validation and ultimately improving outcomes for this lethal breast cancer subtype.

 

Verena Martinez‐Rodriguez, Suguru Ogata, Xiaoping Wang, and Naoto T Ueno. Reprogramming the Immune Landscape of Inflammatory Breast Cancer. Advanced Science.